Skip to main content
. Author manuscript; available in PMC: 2020 May 17.
Published in final edited form as: Pharm Res. 2019 May 17;36(7):104. doi: 10.1007/s11095-019-2629-0

Figure 1.

Figure 1.

A. EBOV activity of various compounds using EBOV infected HeLa cells 24 hours post infection. Error bars represent the SD. B. Cytotoxicity of natural product compounds using HeLa cells. Error bars represent the SD.